Chong Kun Dang Signs Agreement with U.S.-based Kiora for Domestic Development and Commercialization of Retinal Disease Treatment
Chong Kun Dang is embarking on the development of a retinal disease treatment in partnership with the U.S. biotech company Kiora Pharmaceuticals. Chong Kun Dang recently announced that it has signed an agreement to secure exclusive rights for the domestic development and commercialization of a retinal disease treatment candidate currently being developed by Kiora.
The candidate being introduced is gaining attention as an innovative new drug for the treatment of retinal diseases. In particular, the substance has been recognized for its technical potential at a level similar to the U.S. Food and Drug Administration's (FDA) 'Breakthrough Device Designation (BDD)' program, raising expectations that it will provide new treatment opportunities for domestic patients with retinal diseases.
The FDA's BDD program is granted to technologies that treat life-threatening or irreversible conditions when they demonstrate the potential for significant improvement over existing therapies. This collaboration is interpreted as a strategic move by Chong Kun Dang to elevate the standard of retinal disease treatment in the domestic market based on this technological capability.
Through this agreement, Chong Kun Dang plans to further strengthen its position in the domestic retinal disease treatment market. The company stated that it will proceed with clinical trials and regulatory approval processes without setbacks, striving to ensure that domestic patients can benefit from a better treatment environment.
This partnership serves as a case of a domestic pharmaceutical company collaborating with a global biotech firm to introduce an innovative new drug, and it is expected to bring positive changes to the domestic ophthalmic disease treatment market.